This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Phenothiazines

Authoring team

Phenothiazine itself is a veterinary anthelmintic, but the name is also used to denote a group of major tranquillisers resembling phenothiazine in molecular structure.

Phenothiazines were the first effective neuroleptics to be introduced and they are still commonly used. Over 20 clinically active preparations are available but only three broad types are required:

  • a sedative neuroleptic, for example chlorpromazine
  • a less sedating preparation, like trifluoperazine
  • a long acting derivative for maintenance treatment, for example fluphenazine decanoate

Some authorities divide the phenothiazines into:

  • Group 1 - generally characterised by pronounced sedative effects and moderate anti-muscarinic and extrapyramidal side effects. Includes chlorpromazine, methotrimepazine and promazine

  • Group 2 - moderate sedative effects, marked antimuscarinic effects but fewer extrapyramidal side effects than groups 1 or 3. Includes pericyazine, pipothiazine and thioridazine

  • Group 3 - fewer sedative effects, fewer antimuscarinic effects but more pronounced extrapyramidal side effects than groups 1 or 2. Includes fluphenazine, perphenazine, prochlorperazine and trifluoperazine

The phenothiazines, in particular, chlorpromazine, may cause photosensitivity characterised by burning, erythema, swelling and later, frank eczematous changes.


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.